Rybelsus arrives with strict fasting instructions

Rybelsus, the first oral GLP-1 drug approved in the United States, hit the market on September 20, 2019, for adults with type 2 diabetes ^[2]. From the start, its label carried a strict instruction: take the tablet on an empty stomach with no more than 4 ounces of plain water, then wait 30 minutes before eating, drinking anything else, or taking other oral medicines ^[1][2]. That routine became the drug's defining feature — and, years later, its main point of comparison when a very different kind of oral GLP-1 pill reached pharmacies.

The fasting rule exists because of how Rybelsus is built. The tablet uses an absorption enhancer called SNAC to help the semaglutide molecule survive the stomach and get into the bloodstream. Even with that enhancer, only about 0.4% to 1% of each dose is actually absorbed, and food or extra liquid can cut that further ^[1]. Skipping the routine does not make the pill dangerous, but it can mean getting less of the intended dose.

On April 1, 2026, the FDA approved a different kind of oral GLP-1 medicine, orforglipron, sold under the brand name Foundayo, for chronic weight management in adults with obesity or with overweight plus at least one weight-related health condition ^[1]. Unlike Rybelsus, orforglipron is a small, nonpeptide molecule that does not rely on an absorption enhancer, so its label allows patients to take it at any time of day, with or without food ^[1]. Coverage of the approval highlighted this difference directly, framing Foundayo's lack of restrictions as a formulation milestone compared with the fasting rules patients had followed with Rybelsus since 2019 ^[1].

In the pivotal ATTAIN-1 trial, which enrolled 3,127 adults without diabetes, participants taking the highest orforglipron dose (36 mg) lost an average of 11.2% of body weight at 72 weeks, compared with 2.1% on placebo ^[1][7]. Using a stricter analysis that counted only people who stayed on treatment, the 36-mg group lost about 27.3 pounds (12.4%) versus 2.2 pounds (0.9%) with placebo ^[1]. More than half of that group lost at least 10% of their body weight [7]. Side effects leading people to stop the drug occurred in 5.3% to 10.3% of participants across doses, versus 2.7% on placebo, and were mostly gastrointestinal, similar to other GLP-1 drugs ^[1].

Why it matters for patients

For people who found the Rybelsus routine hard to maintain — timing pills before coffee, breakfast, or morning medications — a pill without those restrictions could simplify a daily habit. Lilly's chief executive has said fewer than 1 in 10 people who could benefit from a GLP-1 medicine are currently taking one, citing access, stigma, and other barriers ^[1]. Convenience is only one factor in that gap; cost and insurance coverage matter too. Eligible patients with commercial insurance may pay as little as $25 a month for Foundayo with a manufacturer savings card, while self-pay pricing starts at $149 a month for the lowest dose, and Medicare Part D beneficiaries may be able to get it for $50 a month starting July 1, 2026 ^[1].

It is worth noting that Rybelsus itself has changed since 2019. A newer, higher-dose formulation of oral semaglutide was renamed Ozempic tablets in January 2026, and Wegovy tablets were approved in December 2025 — both still peptide-based products that carry the same fasting instructions as the original Rybelsus ^[2].

What happens next

Orforglipron is also being studied for type 2 diabetes, and Lilly has said a U.S. submission for that use is planned, though it has not yet been approved for diabetes ^[1][8]. Full results from a related trial in adults with diabetes, ATTAIN-2, were published in November 2025, but FDA action on that indication is not yet known [8].